Squamous cell carcinoma of the esophagus l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 40

SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS PowerPoint PPT Presentation


  • 136 Views
  • Updated On :
  • Presentation posted in: General

SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS . GENERAL THORACIC SURGERY CHAPTER 143. ETIOLOGY. No specific etiology agent. Poverty and malnutrition. High dietary content of nitrosamines, nitrites. Tobacco, betel nut, chronic esophageal irritation. Lye burn.

Download Presentation

SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Squamous cell carcinoma of the esophagus l.jpg

SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS

GENERAL THORACIC SURGERY

CHAPTER 143


Etiology l.jpg

ETIOLOGY

  • No specific etiology agent.

  • Poverty and malnutrition.

  • High dietary content of nitrosamines, nitrites.

  • Tobacco, betel nut, chronic esophageal irritation.

  • Lye burn.

  • Achalasia, peptic reflux esophagitis.


Pathology l.jpg

Pathology

  • Rare below age 30.

  • Common located in middle-third(carina to inferior pulmonary vein).

  • Microscopic feature—

    Early-stage esophageal cancer—intraepitherlial, intramucosal, submucosal carcinoma.

    No lymph node metastases.


Molecular biology l.jpg

Molecular biology

  • p53 gene mutation in invasive lesion.

  • Over expression of HER2/new.

  • Amplification of cyclin D gene.

  • Frequent mutation p16 multiple suppressor cyclin-dependent kinase 4 inhibitor gene.


Metastases l.jpg

Metastases

  • Direct extension.

  • Lymphatic metastases (60%).

  • Hematogenous metastases(50-63%).

  • Distal metastases — 25-30% at time of diagnosis.


Metastases7 l.jpg

Metastases

  • Intraesophageal spread—microscopic spread is greater than macroscopic spread.

  • Submucosal lymphatic spread occurs often, may result in tumor emboli producing skip or satellite nodules.


Metastases9 l.jpg

Metastases

  • Direct extension—tumor penetrating adventitial layer.

  • Upper third invasion to mediastinum, great vessel, trachea, recurrent laryngeal nerve.

  • Middle third invasion to pleura, left main bronchus, aorta, pericardium.

  • Lower third invasion to diaphragm stomach.


Metastases10 l.jpg

Metastases

  • Lymphatic spread—the direction of esophageal lymph flow is longitudinal, cephalad or caudad.

  • Upper third tend to be cephalad.

  • Lower two third is caudad, incidence 40-60%.

  • Related to depth and extent of invasion.


Lymph node station l.jpg

Lymph node station

  • 1 — the paraesophageal lymph node.

  • 2 — periesophageal, celiac perigastric lymph node.

  • 3 — the distal subdiapgragm or supraclavicular, lateral thoracic region.


Clinical manifestation l.jpg

Clinical manifestation

  • s/s — infrequently at early stage.

  • Retrosternal discomfort, pain sensatin of frication, burning.

  • Slow passage of food during swallowing.

  • Progressive dysphagia — first solid food, then soft food, then liquid.

  • Melena, hematemess, anemia, weight loss, hoarseness, hiccough, cachexia.


Diagnostic studies l.jpg

Diagnostic studies

  • Cytologic screening

  • Upper GI series

  • CT

  • Endoscopy

  • Endoscopic ultrasonography

  • Bronchoscopy: evaluation the tracheal or bronchial invasion.


Cytologic screening l.jpg

Cytologic screening

  • Screen asymptomatic people in high-incidence area.

  • Obtain smear of esophageal mucosa with abrasive balloon catheter.


Upper gi series l.jpg

Upper GI series

  • Diffucult in demonstration the early lesion

  • Length of lesion, not correlate with degree of tumor penetration.

  • Longer than 10 cm is incurable.

  • Esophageal axis, 74% tumor penetrated wall associated with axis abnormalities.

  • Demonstration tracheoesophageal fistula.


Slide19 l.jpg

CT

  • Four stage —

    I — intralumonal mass without wall thickening.

    II — wall thickening.

    III — tumor spread into adjacent tissue.

    IV — distal meatastases.

  • Identified lymph node.

  • Aortic invasion: loss fat planes and contact less hen 45 degree — invasion unlikely; exceed 90 degree — invasion real possibility.

  • Invasion to pericardium is difficult to detect.


Endoscopy l.jpg

Endoscopy

  • Essential in all patients.

  • Biopsy should be done in all cases.

  • Positive diagnosis 90%.

  • If no lesion—mucosal stain—

    Toluidine blue stain — the tumor cell not the normal nucosa.

    Lugol’s solution stain — the normal cell not the tumor cell.


Endoscopic ultrasonography l.jpg

Endoscopic ultrasonography

  • —detailed studies the structure of esophageal wall and periesophageal tissue.


Staging l.jpg

Staging

  • —TNM system.


Surgical therapy l.jpg

Surgical therapy

  • Transthoracic, trandhiatal esophagectomy.

  • Reconstruction.

  • Respectability rate—45%-56%.

  • Morbidity—most respiratory complication.

  • Mortality—0.8%-12%.

  • Surgical result—long-term survival is poor.


Resection plus adjuvant therapy l.jpg

Resection plus adjuvant therapy

  • Preoperative radiation therapy

  • Postoperative irradiation


Preoperative radiation therapy l.jpg

Preoperative radiation therapy

  • Tumor became smaller and softer.

  • Less infiltrating tissue plane develop.

  • Increase respectability.

  • Long term survival unchanged.


Postoperative irradiation l.jpg

Postoperative irradiation

  • No survival advantage.

  • Significant reduction in local recurrence.

  • High incidence of complication related the transposed intrathoracic stomach.


Chemotherapy l.jpg

Chemotherapy

  • Response rate — 40-60%.

  • Neoadjuvant chemotherapy.


Fate of surgically resected patient l.jpg

Fate of surgically resected patient

  • Survive more than 5 year tend to have the follow prognostic factors—

    Small tumor less than 5 cm long.

    No invasion to advantia.

    No lymph node involvement.

    Age younger than 60 year.

    Women.


Radiation therapy l.jpg

Radiation therapy


  • Login